Canhelp Genomics

Canhelp Genomics is a commercial-stage, China-based leader in AI-powered precision oncology, delivering clinically validated diagnostic solutions for early cancer detection and personalized treatment. With more than a decade of clinical-grade development and 50+ granted patents, we integrate proprietary RNA profiling with an advanced AI platform to deliver unmatched accuracy, efficiency, and scalability. Our suite of AI-powered precision oncology diagnostics have achieved several industry-defining milestones Canhelp®-Origin The world’s only China NMPA- and CE-IVD dual-approved AI+RNA pan-cancer diagnostic test. A randomized Phase 3 trial published in The Lancet Oncology showed a 32% improvement in patient survival, positioning it as a potential global standard-of-care. Canhelp®-MSI A deep-learning solution for microsatellite instability detection that reduces pathology workload by 90% while accelerating turnaround time. It is designated by China’s NMPA as a “Breakthrough Device,” the first AI-driven Class digital pathology product in the country. Canhelp®-UCa The first NMPA- and CE-IVD-approved urine RNA liquid biopsy for urothelial carcinoma, enabling noninvasive early detection and recurrence monitoring. Canhelp®-PCa (pipeline) A next-generation urine RNA test targeting the USD 800 million prostate cancer diagnostics market, with promising early performance for high-risk patient identification. Backed by leading physicians and clinical centers across Asia and Europe, Canhelp Genomics has established strong global credibility and adoption. Our ISO-13485-certified GMP facilities in Hangzhou and Suzhou support an annual capacity of over tests, while our dedicated AI research center accelerates the expansion of our precision oncology pipeline.